請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49863
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李啟明 | |
dc.contributor.author | Po-Lin Chen | en |
dc.contributor.author | 陳柏霖 | zh_TW |
dc.date.accessioned | 2021-06-15T11:53:21Z | - |
dc.date.available | 2026-12-31 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-11 | |
dc.identifier.citation | 1. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2S-8S.
2. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999;274:22903-6. 3. Bjorkman DJ. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998;105:8S-12S. 4. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82. 5. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42. 6. McAdam BF, Mardini IA, Habib A, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-82. 7. Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol 2001;64:327-63. 8. Zeilhofer HU. Prostanoids in nociception and pain. Biochem Pharmacol 2007;73:165-74. 9. Engblom D, Saha S, Engstrom L, et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci 2003;6:1137–8. 10. Ivanov AI, Romanovsky AA. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci 2004;9:1977-93. 11. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of non-pharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465-74. 12. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61. 13. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52:930-45. 14. Dionne RA, Berthold CW. Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry. Crit Rev Oral Biol Med 2001;12:315-30. 15. Marjoribanks J, Ayeleke RO, Farquhar C, et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2015;7:CD001751. 16. Eccles R, Loose I, Jawad M, et al. Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection. Pain Med 2003;4:118-24. 17. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106:3S-12S. 18. Bjarnason I, MacPherson AJS. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994;62:145-57. 19. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:1-138. 20. Adams DH, Howie AJ, Michael J, et al. Non-steroidal anti-inflammatory drugs and renal failure. Lancet 1986;1:57-60. 21. Haragsim L, Dalal R, Bagga H, et al. Ketorolac-induced acute renal failure and hyperkalemia: report of three cases. Am J Kidney Dis 1994;24:578-80. 22. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998;338:446-52. 23. Dunn M. The role of arachidonic acid metabolites in renal homeostasis: non-steroidal anti-inflammatory drugs, renal function and biochemical, histological and clinical effects and drug interactions. Drugs 1987;33:56-66. 24. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S. 25. Brater DC. Renal effects of cyclooxygyenase-2-selective inhibitors. J Pain Symptom Manage 2002;23:S15-20. 26. Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70-83. 27. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151:488-96. 28. Lafrance JP, Miller DR. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf 2009;18:923-31. 29. Ungprasert P, Cheungpasitporn W, Crowson CS, et al. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015;26:285-91. 30. Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110:20S-7S. 31. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006;164:881-9. 32. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal Anti-Inflammatory Drugs and Risk of ARF in the General Population. Am J Kidney Dis 2005;45:531-9. 33. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013;346:e8525. 34. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239. 35. Nevins M, Berque S, Corwin N, et al. Phenylbutazone and pulmonary oedema. Lancet 1969;2:1358. 36. Tashima CK, Rose M. Pulmonary edema and salicylates. Ann Intern Med 1974;81:274-5. 37. Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977;237:1716-7. 38. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002;89:10D-7D. 39. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41. 40. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35:209-19. 41. Armstrong EP, Malone DC. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003;25:1-18. 42. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med 2014;161:690-8. 43. Santilli F, Davi G, Basili S, et al. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost 2010;8:914-22. 44. Kalafutova S, Juraskova B, Vlcek J. The impact of combinations of non-steroidal anti-inflammatory drugs and anti-hypertensive agents on blood pressure. Adv Clin Exp Med 2014;23:993-1000. 45. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108-12. 46. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777-84. 47. Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002;162:265-70. 48. Huerta C, Varas-Lorenzo C, Castellsague J, et al. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92:1610-5. 49. Ungprasert P, Srivali N, Kittanamongkolchai W. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis. Eur J Intern Med 2015;26:685-90. 50. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003;14:240-6. 51. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141-9. 52. Hudson M, Rahme E, Richard H, et al. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum 2007;57:516-23. 53. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42. 54. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-70. 55. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20. 56. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300. 57. WHO Collaborating Centre for Drug Statistics. URL: http://www.whocc.no/ddd/definition_and_general_considera/. 58. Tannenbaum H, Bombardier C, Davis P, et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57. 59. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008;64:233-52. 60. Gaziano JM. Nonnarcotic analgesics and hypertension. Am J Cardiol 2006;97:10-6. 61. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002;89:18D-25D. 62. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85:190-7. 63. Shau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord 2012;12:4. 64. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-13. 65. Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J 2013;6:8-14. 66. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12. 67. Chiong JR, Cheung RJ. Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry? Korean Circ J 2013;43:287-92. 68. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63. 69. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13:1161-7. 70. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015;63:2227-46. 71. MacFarlane LL, Orak DJ, Simpson WM. NSAIDs, antihypertensive agents and loss of blood pressure control. Am Fam Physician 1995;51:849-56. 72. Aljadhey H, Tu W, Hansen RA, et al. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord 2012;12:93. 73. Fournier JP1, Sommet A, Bourrel R, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol 2012;68:1533-40. 74. Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol 2010;3:769-76. 75. Wang KL, Liu CJ, Chao TF, et al. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol. 2014;177:86-90. 76. Shih CJ, Lee YJ, Lo YH, et al. Association between use of dipeptidyl peptidase-4 inhibitors and the risk of acute kidney injury: a nested case-control study. Mayo Clin Proc Available online: 26 May 2016. 77. Choi KH, Kim AJ, Son IJ, et al. Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. J Korean Med Sci 2010;25:337-41. 78. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70. 79. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17. 80. Jaarsma T. Health care professionals in a heart failure team. Eur J Heart Fail 2005;7:343-9. 81. Grady KL, Dracup K, Kennedy G, et al. Team management of patients with heart failure: a statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. Circulation 2000;102:2443-56. 82. McCormick N, Lacaille D, Bhole V, et al. Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis. PLoS One 2014;9:e104519. 83. Waikar SS, Wald R, Chertow GM, et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006;17:1688-94. 84. Demant MN, Gislason GH, Kober L, et al. Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study. Diabetologia 2014;57:1595-600. 85. Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49863 | - |
dc.description.abstract | 背景: 文獻報導大眾族群使用非類固醇抗發炎藥與急性腎損傷的發生有關,而後續研究也顯示心衰竭病人使用此類藥品會增加因心衰竭的住院率。臨床上,醫師經常處方非類固醇抗發炎藥以緩解退化性關節炎、痛風與上呼吸道感染等症狀。一旦心衰竭病人暴露到此類藥品,可能會發生急性腎損傷,進而惡化其心衰竭病情,但目前少有文獻探討心衰竭病人使用非類固醇抗發炎藥造成急性腎損傷的風險因子。
目的: 藉由回溯病歷建立某醫學中心資料庫,探討心衰竭病人使用非類固醇抗發炎藥造成急性腎損傷之機率,並找出潛在風險因子,藉此突顯藥師及個案管理師在心衰竭病人用藥安全與健康照護的重要性。 方法: 本研究為一病歷回顧世代性研究,利用個案報告表彙集某一醫學中心心衰竭門診病人資料。自2006年1月1日至2016年1月31日被診斷有心衰竭的病人,若期間曾經使用非類固醇抗發炎藥,每一次暴露(exposure)作為一個事件(episode),暴露的第一天定義為進入研究世代日期(cohort entry date),並且在當天記錄病人的年齡、血清肌酸酐濃度、左心室射出率、共病症等基礎特徵、併用藥品,每個事件會追蹤至最近一次心衰竭門診就診日,定義為visiting date (VD),且在當天評估病人是否發生試驗目標(study outcomes)。主要試驗目標定義為急性腎損傷(VD的血清肌酸酐濃度比基礎值上升≥0.5 mg/dL);次要試驗目標包括收縮壓上升(VD的收縮壓≥140 mmHg,且比基礎收縮壓上升≥5 mmHg)、下肢水腫惡化(VD的水腫程度比上次門診更嚴重)。資料分析利用描述性分析,描述有無發生試驗目標者之間,基礎特性、併用藥品與非類固醇抗發炎藥開方模式等差異。 結果: 本研究共收納145位病人、91個非類固醇抗發炎藥暴露事件。排除8個末期腎疾病的事件,剩餘83個事件,由於有37個事件在VD沒有血清肌酸酐濃度的檢驗數值,因此,在主要試驗目標剩餘的46個事件適合做分析,當中有5個事件發生急性腎損傷(10.9%),這群病人的基礎血清肌酸酐濃度(1.6 vs. 1.1 mg/dL, p=0.01)與血清尿素氮(29.7 vs. 19.5 mg/dL, p=0.01)較高、糖尿病(80.0% vs. 26.8%, p=0.03)與慢性腎疾病(80.0% vs. 22.0%, p=0.02)的盛行率較高;在次要試驗目標中,2個事件沒有血壓的紀錄,剩餘的81個事件中有10個發生收縮壓上升(12.4%),這些病人的年紀較大(77.5 vs. 65.0 歲, p<0.01)、基礎收縮壓(137.5 vs. 123.0 mmHg, p=0.03)與脈搏壓(63.0 vs. 50.0 mmHg, p=0.02)較高;此外,1個事件沒有下肢水腫的紀錄,在82個當中有10個事件發生下肢水腫惡化(12.2%),這些病人的基礎血清尿素氮較高(23.9 vs. 18.0 mg/dL, p=0.04)、使用indomethacin的比例較高(20.0% vs. 1.4%, p=0.04)。 結論: 本研究證明心衰竭病人使用非類固醇抗發炎藥造成急性腎損傷的個案,為一群基礎腎功能較差、糖尿病與慢性腎疾病盛行率較高的病人;發生收縮壓上升的個案,為一群年紀較高的老年人(定義為≥75歲),以及基礎收縮壓與脈搏壓較高的病人;發生下肢水腫惡化的個案,為一群基礎血清尿素氮較高、使用indomethacin比較較高的病人。 | zh_TW |
dc.description.abstract | Background: Previous studies found that non-steroidal anti-inflammatory drugs (NSAIDs) were associated with acute kidney injury (AKI) in general population, thereafter some studies showed that NSAIDs might increase the rate of heart failure (HF) hospitalization in HF patients. In clinical practice, physicians usually prescribe NSAIDs for reliving the symptoms of osteoarthritis, gout, or upper respiratory infection. Once HF patients are exposed to these drugs, they may develop AKI which could deteriorate the condition of HF. However, there is few study to explore the risk factors of AKI in HF patients exposed to NSAIDs.
Objective: We reviewed the medical records to establish the database of the selected medical center and to study the risk factors associated with AKI in HF patients exposed to NSAIDs. We would address the importance of pharmacists and case managers in engaging medication safety and healthcare for HF patients. Methods: This is a retrospective cohort study by using medical record review. The patients’ information was collected by the case report form and these patients who had been diagnosed with HF have been followed up at the specialized HF clinic over a 10-year interval from January 1, 2006, through January 31, 2016. Study episode was defined as a patient who was ever exposed to NSAID and each exposure was regarded as one episode. The date of the initial NSAID prescription was defined as the cohort entry date. We documented the baseline characteristics (including age, serum creatinine (SCr), left ventricular ejection fraction, comorbidities) and concomitant medications at the cohort entry date. Each episode was followed from the cohort entry date to the nearest specialized HF clinic visit, and the date was assigned as visiting date (VD). At the VD, we evaluated the study outcomes as follows: primary outcome as AKI, defined as the change of SCr from baseline ≥0.5 mg/dL; one of secondary outcomes as elevated systolic blood pressure (SBP), defined as the SBP of VD ≥140 mmHg and the change of SBP from baseline ≥5 mmHg; the other secondary outcome as aggravated leg edema, defined as the exacerbation of leg edema compared to the last clinic visit. Descriptive analysis was used for depicting the distribution between with- and without-outcome groups including baseline characteristics, concomitant medications and the patterns of NSAIDs prescription. Results: A total of 145 patients were included, and there were 91 episodes ever exposed to NSAIDs. Because 8 end-stage renal disease episodes were excluded, 83 episodes remained in the study. In the primary outcome, since 37 episodes were dearth of SCr detection on VD, there were 46 evaluable episodes. A total of 5 out of 46 episodes (10.9%) developed AKI. Not only were their baseline SCr (1.6 vs. 1.1 mg/dL, p=0.01) and BUN (29.7 vs. 19.5 mg/dL, p=0.01) higher than those of episodes in the non-AKI group, but they were also prevalent in diabetes mellitus (DM) (80.0% vs. 26.8%, p=0.03) and chronic kidney disease (CKD) (80.0% vs. 22.0%, p=0.02). In secondary outcome as elevated SBP, because of the absence of BP documentation in 2 episodes, remaining 81 episodes were eligible. A total of 10 out of 81 episodes (12.4%) presented with this outcome, and they were the extreme elderly (77.5 vs. 65.0 years, p<0.01) with higher baseline SBP (137.5 vs. 123.0 mmHg, p=0.03) and pulse pressure (63.0 vs. 50.0 mmHg, p=0.02). In addition, as a result of the missing of leg edema documentation in 1 episode, 82 episodes were eligible for the other secondary outcome as aggravated leg edema. A total of 10 out of 82 episodes (12.2%) developed this outcome, and they were with higher blood urea nitrogen level (23.9 vs. 18.0 mg/dL, p=0.04) and the higher proportion of indomethacin use (20.0% vs. 1.4%, p=0.04). Conclusion: This study demonstrates that the distributions of HF patients exposed to NSAIDs who developed AKI were with worse baseline renal function and prevalent in DM and CKD; who presented with elevated SBP were the extreme elderly (≥75 years) and with higher baseline SBP and pulse pressure; who manifested as aggravated leg edema were with higher baseline BUN level and more indomethacin use. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:53:21Z (GMT). No. of bitstreams: 1 ntu-105-R03451008-1.pdf: 2586256 bytes, checksum: 1cb57f7928472084df95b7e50416d3d3 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 誌謝 ..................................................................................................i
Abbreviation List ...............................................................................iii 中文摘要 ..........................................................................................iv Abstract ..........................................................................................vi Contents ..........................................................................................ix Table Contents .............................................................................. xi Figure Contents............................................................................. xii Chapter 1 Introduction .....................................................................1 Section 1 Literature Review .............................................................1 1.Pharmacological Properties and Clinical Therapy of NSAIDs......1 2.NSAIDs and Acute Kidney Injury.................................................3 3.NSAIDs and Heart Failure...........................................................5 Section 2 Research Motivation.........................................................7 Section 3 Research Purposes......................................................... 8 Chapter 2 Methods ...........................................................................9 Section 1 Study Population..............................................................9 Section 2 Study Procedures and Study Outcomes...........................10 Section 3 Exposure Definition..........................................................12 Section 4 Covariate Information.......................................................13 Section 5 Statistical Analysis...........................................................14 Section 6 Ethical Consideration.......................................................14 Chapter 3 Results..............................................................................15 Section 1 Baseline Characteristics...................................................15 Section 2 Acute Kidney Injury...........................................................16 Section 3 Elevated Systolic Blood Pressure.....................................18 Section 4 Aggravated Leg Edema.....................................................20 Chapter 4 Discussion..........................................................................21 Section 1 Acute Kidney Injury............................................................21 Section 2 Elevated Systolic Blood Pressure.......................................23 Section 3 Aggravated Leg Edema......................................................25 Section 4 Strengths...........................................................................26 Section 5 Limitations.........................................................................27 Section 6 Suggestion for Clinical Practice.........................................28 Section 7 Future Work.......................................................................30 Chapter 5 Conclusion..........................................................................32 References...........................................................................................33 Appendix..............................................................................................74 Case Report Form..............................................................................74 | |
dc.language.iso | en | |
dc.title | 心衰竭病人使用非類固醇抗發炎藥產生急性腎損傷之風險評估 | zh_TW |
dc.title | Risk of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)-Induced Acute Kidney Injury in Heart Failure Patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 沈麗娟,蕭斐元 | |
dc.subject.keyword | 心臟衰竭,非類固醇抗發炎藥,急性腎損傷,風險因子,病歷回顧研究, | zh_TW |
dc.subject.keyword | Heart failure,Non-steroidal anti-inflammatory drugs (NSAIDs),Acute kidney injury,Risk factors,Medical record review, | en |
dc.relation.page | 81 | |
dc.identifier.doi | 10.6342/NTU201601736 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 2.53 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。